Design and Evaluation of RNA Aptamer-Mediated Delivery of C/EBPβ siRNA for Oncological Therapy

被引：0
作者：
Vasconcelos, D. [1 ,2 ]
Sodergren, M. H. [1 ]
Reebye, V. [1 ]
Vasara, J. [1 ]
Song, M. S. [3 ]
Holm, K. [3 ]
Khorsandi, S. E. [1 ]
Rossi, J. [3 ]
Habib, N. [1 ,2 ]
Huang, K. W. [4 ,5 ]
机构：
[1] Imperial Coll London, Dept Surg & Canc, London, England
[2] Apterna Ltd, London SW1P 2PN, England
[3] Beckman Res Inst City Hope, Dept Mol & Cellular Biol, Duarte, CA USA
[4] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan
来源：
JOURNAL OF NUCLEIC ACIDS | 2025年 / 2025卷 / 01期
关键词：
PANCREATIC DUCTAL ADENOCARCINOMA; TRANSFERRIN RECEPTOR; TARGETED DELIVERY; CANCER; ALPHA; LIVER; CARCINOMA; IMMUNOTHERAPY; GROWTH; CELLS;
D O I：
10.1155/jna/1461574
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The CCAAT/enhancer-binding protein beta (CEBPB or C/EBP beta) is a transcription factor that plays a critical role in cellular differentiation, metabolism, and immune response. Emerging evidence has highlighted its complex involvement in both solid and hematological cancers, such as hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC), where it can act as an oncogene or a tumor suppressor, depending on the context. In this study, we describe the design and evaluation of a conjugate formed by a small interfering RNA (siRNA) for CEBPB and a transferrin receptor targeting aptamer (TfR-siCEBPB). The designed conjugate is active in human and mouse cells, by transfection and by passive uptake, demonstrating target engagement with strong downregulation of CEBPB mRNA transcript. In murine models of metastatic PDAC and cirrhotic HCC, treatment with TfR-siCEBPB was associated with reduction in tumor burden and improvement in liver function biomarkers. This novel aptamer conjugate allows delivery of targeted oligonucleotide therapy and is a promising therapeutic tool to take forward to human trials.
引用
收藏
页数：14
相关论文
共 53 条
[1]   Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma [J].
Adachi, Makiko ;
Kai, Keita ;
Yamaji, Koutaro ;
Ide, Takao ;
Noshiro, Hirokazu ;
Kawaguchi, Atsushi ;
Aishima, Shinichi .
HISTOPATHOLOGY, 2019, 75 (01) :63-73
[2]   Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome [J].
Andrikakou, Pinelopi ;
Reebye, Vikash ;
Vasconcelos, Daniel ;
Yoon, Sorah ;
Voutila, Jon ;
George, Andrew J. T. ;
Swiderski, Piotr ;
Habib, Robert ;
Catley, Matthew ;
Blakey, David ;
Habib, Nagy A. ;
Rossi, John J. ;
Huang, Kai-Wen .
NUCLEIC ACID THERAPEUTICS, 2022, 32 (06) :486-496
[3]   Pancreatic cancer: yesterday, today and tomorrow [J].
Ansari, Daniel ;
Tingstedt, Bobby ;
Andersson, Bodil ;
Holmquist, Fredrik ;
Sturesson, Christian ;
Williamsson, Caroline ;
Sasor, Agata ;
Borg, David ;
Bauden, Monika ;
Andersson, Roland .
FUTURE ONCOLOGY, 2016, 12 (16) :1929-1946
[4]   CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells [J].
Barakat, D. J. ;
Zhang, J. ;
Barberi, T. ;
Denmeade, S. R. ;
Friedman, A. D. ;
Paz-Priel, I. .
ONCOGENE, 2015, 34 (48) :5912-5922
[5]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[6]   Development of Better Aptamers: Structured Library Approaches, Selection Methods, and Chemical Modifications [J].
Brown, Alex ;
Brill, Jake ;
Amini, Ryan ;
Nurmi, Connor ;
Li, Yingfu .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2024, 63 (16)
[7]   CCAAT/enhancer binding protein α (CIEBPα) is an important mediator of mouse C/EBPβ protein isoform production [J].
Burgess-Beusse, BL ;
Timchenko, NA ;
Darlington, GJ .
HEPATOLOGY, 1999, 29 (02) :597-601
[8]  
Calkhoven CF, 2000, GENE DEV, V14, P1920
[9]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[10]   The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells [J].
Daniels, Tracy R. ;
Delgado, Tracie ;
Helguera, Gustavo ;
Penichet, Manuel L. .
CLINICAL IMMUNOLOGY, 2006, 121 (02) :159-176
123456